Navigation Links
Hepatitis B Foundation and AAPCHO Sponsor Congressional Briefing on 'Zero Tolerance for Hepatitis B'
Date:5/20/2008

Spotlights National Hepatitis B Awareness Week

DOYLESTOWN, Pa., May 20 /PRNewswire-USNewswire/ -- Recognizing National Hepatitis B Awareness Week May 19 - 23, 2008, the Hepatitis B Foundation and the Association of Asian Pacific Community Health Organizations (AAPCHO) is hosting a Congressional briefing, "Zero Tolerance for Hepatitis B: the Health Needs of Women and Children," on May 20 at the U.S. Capitol with special guests Congressmen Mike Honda (CA) and Charles Dent (PA). It will call urgent attention to the health needs of pregnant women infected with hepatitis B and the protection of their newborns against this deadly virus. Patients and experts from the CDC and Johns Hopkins University Hospital have been invited to testify.

"With the availability of an effective vaccine and six approved therapies for chronic hepatitis B, no woman or child should be left behind," says Dr. Timothy Block, co-founder and president, Hepatitis B Foundation. With good vaccines and treatment options, the U.S. has the tools to effectively implement a zero tolerance policy against hepatitis B to protect the health of Americans.

Hepatitis B is the deadliest disease that can be prevented through infant vaccination. In the U.S., approximately 20,000 babies are born yearly to women with hepatitis B. Despite a national requirement that all newborns be vaccinated at birth against the hepatitis B virus (HBV), up to 1,500 newborns are chronically infected with HBV. Twenty-five percent will die prematurely from liver failure or cancer, usually in the prime of their adult lives.

There are national guidelines requiring all pregnant women be tested for hepatitis B and recommendations to educate and refer infected women to care. Local and state health departments lack necessary resources to implement the recommendations. According to Jeff Caballero, executive director, AAPCHO, "This gap in care results in jeopardizing the health of these infected women and continues the devastating cycle of maternal HBV transmission between mother and her newborn."

Hepatitis B is the world's most serious common liver infection transmitted through blood, sex, drug use, and from an infected woman to her newborn. It is the primary cause of liver cancer, which is the fastest growing cancer in the U.S. Worldwide, one million people die from hepatitis B each year.

Guest speakers at the May 20 Congressional briefing include Dr. Kathleen Schwarz, director, Pediatric Liver Center, Johns Hopkins University School of Medicine; Dr. Mack Mitchell, chief, Division of Gastroenterology, Johns Hopkins Bayview Medical Center; Dr. Chong Gee Teo, chief, Laboratory Branch, Division of Viral Hepatitis, CDC; Mr. Ted Fang, director, AsianWeek Foundation; and personal testimonies from California Assemblywoman Fiona Ma and Lucy C.

Hepatitis B Foundation is dedicated to finding a cure and improving the quality of life for those affected with hepatitis B worldwide. http://www.hepb.org.

Association of Asian Pacific Community Health Organizations represents community health organizations dedicated to the health of Asian Americans. http://www.aapcho.org.

Contact: Leah Rice

215-340-0480 / leah@furiarubel.com Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Dr. Timothy Block http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=66704 Joan Block http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=66707


'/>"/>
SOURCE Hepatitis B Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
4. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
7. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
8. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
10. Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
11. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... International, a not-for-profit organization focused on the ethics and governance ... to patients around the world, today announced that the editors ... the Good Pharma Scorecard an ,Editors, Pick, ... of BMJ Open ,s ,Most Popular Articles, which includes ... read. Ed Sucksmith , assistant editor of ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... focused on the development and manufacture of biopharmaceuticals and therapeutics, announces an ... the 2016 BioProcess International Awards – Recognizing Excellence in the People, Organizations ...
(Date:2/11/2016)... 2016   BioInformant announces the February 2016 ... Products, Opportunities, Tools, and Technologies – Market Size, Segments, ... The first and only ... industry, BioInformant has more than a decade of historical ... by stem cell type. This powerful 175 page global ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... of its new stem cell treatment clinic in Quito, Ecuador. The new facility ... and trauma applications to patients from around the world. , The new ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 This ... the bioinformatic market by reviewing the recent advances ... tools that drive the field forward. Includes forecast ... Identify the challenges and opportunities that exist ... and software solution developers, as well as IT ...
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
(Date:1/28/2016)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human ... December 31, 2015. --> --> ... 2 percent compared to the comparable quarter last year to $470.5 ... $35.0 million, or $0.93 per diluted share. ... quarter of fiscal 2016 grew 9 percent over the prior year ...
Breaking Biology News(10 mins):